Reasons for treatment modifications of 16 patients
| Patient No | Therapy | Organism | Resistance | Reasons | Modification | Outcome |
| 1 | Fluoroquinolone |
S aureus and (S aureus from leg ulcer) | Cefazolin (resist to all except vanco) | Concern about sensitivity (CAS) | Topical cefazolin, systemic vancomycin, cefrataxone | PED conj flap |
| 2 | Fluoroquinolone | S pneumoniae | — | CAS | Topical cefazolin, penicillin, systemic penicillin | Healing at last exam |
| 3 | Fluoroquinolone | S aureus | — | CAS | Topical vancomycin | Healed |
| 4 | Fluoroquinolone | P acnes | — | CAS | Topical tobramycin | PED SBCL applied |
| 5 | Fluoroquinolone | S pneumoniae | — | CAS | Topical cefazolin | Healing at last exam |
| 6 | Fluoroquinolone | Moraxella | — | Deterioration Hypopyon developed | Topical cefazoloin | Healed |
| 7 | Fortified |
S pneumoniae S aureus | — | CAS | Topical vancomycin, systemic cefazolin and ciprofloxacin | PED tarsorrhaphy |
| 8 | Fortified | S haemolyticus | CAS | Subconjunctival gentamicin, systemic ciprofloxacin and penicillin | Eventual enucleation | |
| 9 | Fortified | S sanguis | CAS | To pical vancomycin | Healed | |
| 10 | Fortified | Enterobactor cloacae | Cefazolin | Resistant organism | Topical ciprofloxacin | Healed |
| 11 | Fortified | Moraxellasp | Cefazolin | Resistant organism | Systemic ciprofloxacin and gentamicin, topical antiviral | PED conj flap |
| 12 | Fortified | P aeruginosa | CAS | Systemic cefazolin, gentamicin, and antiviral | Healing | |
| 13 | Fortified | P aeruginosa | Chloramph enicol | Systemic ticarcillin | Healed | |
| 14 | Fortified | P aeroginosa | Chloramph enicol | Systemic ticarcillin | PED conj flap | |
| 15 | Fortified | Alpha haemolytic strep,S epidermidis, and coag −ve | Deterioration | Systemic cefazolin and tobramycin | PK | |
| 16 | Fortified | S aureus | History of HZO | Systemic ciprofloxacin and topical antiviral | Healed |